The purpose of this review is to summarize drugs containing an azoloazine moiety and exhibiting antidiabetic activity. The review includes azoloazines active against dipeptidyl peptidase-4, α-glucosidase, and glycogen phosphorylase acting as PPARγ and GPR119 receptor agonists, as well as those inhibiting advanced glycation.